MMR vaccine(Hard to Treat Diseases, Inc.)(MMR vaccine(Hard to Treat Diseases, Inc.)) - 在研适应症：麻疹，腮腺炎，风疹_专利_临床

概要

基本信息

药物类型

联合疫苗、预防性疫苗

别名

MMR BERNA、Triviraten、Triviraten Berna

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染口颌疾病其他疾病

在研适应症

麻疹腮腺炎风疹

非在研适应症

脑膜炎球菌感染

原研机构

Hard to Treat Diseases, Inc.

在研机构

Hard to Treat Diseases, Inc.

非在研机构

Novartis Vaccines & Diagnostics SL

权益机构-

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

7

项与 MMR vaccine(Hard to Treat Diseases, Inc.) 相关的临床试验

CTRI/2023/08/055966

/ Not yet recruiting临床4期

Effectiveness of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Plane Warts in Tertiary Health Care Center â?? A Randomized Comparative Control Study. - NA

开始日期2023-08-01

申办/合作机构

Mamc, Inc.

CTRI/2022/12/048166

/ Not yet recruitingN/AIIT

A randomized, placebo-controlled double blinded study to compare the efficacy and safety of intralesional MMR vaccine with normal saline in immunocompetent adults with molluscum contagiosum

开始日期2022-12-18

申办/合作机构-

CTRI/2021/04/033157

/ Not yet recruitingN/AIIT

To compare the efficacy of intralesional MMR vs BCG in the treatment of multiple warts: A randomised controlled trial

开始日期2021-05-10

申办/合作机构

Armed Forces Medical College

100 项与 MMR vaccine(Hard to Treat Diseases, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 MMR vaccine(Hard to Treat Diseases, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 MMR vaccine(Hard to Treat Diseases, Inc.) 相关的专利（医药）

登录后查看更多信息

13

项与 MMR vaccine(Hard to Treat Diseases, Inc.) 相关的文献（医药）

2010-10-01·Vaccine3区 · 医学

Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route

3区 · 医学

Article

作者: D. Castañeda ; J. Fernandez de Castro ; D. Martinez ; John V. Bennett ; José Luis Díaz-Ortega

Information on antibody persistence after aerosol revaccination with MMR components is limited. Thus, antibody titers were determined in 283 adult participants in a MMR vaccine trial 12 months after revaccination. One group had received aerosolized Triviraten vaccine while two other groups received either injected Triviraten or MMR II vaccine. Both MMR vaccines contained the same rubella strain, but different measles and mumps strains. Seropositivity to measles persisted in 98% of aerosolized vaccine recipients, 92% of injected Triviraten, and 95% of injected MMR II. All participants in the three groups retained seropositivity to rubella, while less than 50% remained seropositive to mumps.

2010-01-01·Vaccine3区 · 医学

Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: Comparisons with injected MMR

3区 · 医学

Article

作者: Jose-Raul Vieyra ; Jose Luis Diaz-Ortega ; Jorge Fernandez de Castro ; Jose Luis Valdespino-Gomez ; John V. Bennett ; Deyanira Castaneda

Seroresponses to measles, rubella and mumps were evaluated following the injection of MMR II and injection or aerosol administration of Triviraten in young adults. Response to aerosolized Rubini mumps strain was a focus of interest, given robust responses to aerosolized mumps vaccine (Leningrad-Zagreb strain) in a prior study using aerosolized MMR vaccine. The aerosolized Edmonston-Zagreb (EZ) measles vaccine was significantly more immunogenic than injected EZ vaccine, and comparable to results following injected Moraten measles vaccine having twice the dosage. Responses to rubella were comparable in the three MMR study groups. Aerosolized Rubini vaccine was very highly and unexpectedly less immunogenic than either injected Rubini or Jeryl-Lyn strains. The high attenuation of Rubini vaccine appears to have limited its affinity for respiratory tract receptors, which may underlie its lack of clinical effectiveness.

2006-05-01·Anales de Pediatría4区 · 医学

Seguridad de la vacunación triple vírica en pacientes con alergia al huevo

4区 · 医学

Article

作者: E. Gómez Guzmán ; J. Torres Borrego

In Spain, for many years allergy to eggs was considered to contraindicate vaccines cultured in fibroblasts from chick embryos such as the measles, mumps, rubella (MMR) and influenza vaccines. Consequently, an alternative vaccine (Triviraten Berna) incubated in diploid human cells has been systematically administered to children who are allergic to eggs, without questioning tolerance to the standard MMR vaccine. After Biotech Bern Laboratory discontinued the production of Triviraten, this alternative was no longer available for children with egg allergy, who should receive a first dose of the MMR vaccine at the age of 15 months and a second one (booster dose) at the age of 3 years. In this context, from November 2004 to June 2005, a single dose of the MMR vaccine was administered to 40 children with allergy to eggs and none showed an adverse reaction. We conclude that this vaccine can be safely administered to this group of patients.

100 项与 MMR vaccine(Hard to Treat Diseases, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
麻疹	申请上市	-	Hard to Treat Diseases, Inc.	-
腮腺炎	申请上市	-	Hard to Treat Diseases, Inc.	-
风疹	申请上市	-	Hard to Treat Diseases, Inc.	-
脑膜炎球菌感染	药物发现	英国	Novartis Vaccines & Diagnostics SL	2007-07-01